SanBio Company Limited (4592.T)
JPY 2140.0
(7.0%)
JPY 2140.0
(7.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -14.5 Million JPY | 41.08% |
| 2022 | -24.61 Million JPY | 81.42% |
| 2021 | -132.46 Million JPY | -77.92% |
| 2020 | -74.45 Million JPY | -16756.6% |
| 2019 | 447 Thousand JPY | -39.68% |
| 2018 | 741 Thousand JPY | -99.83% |
| 2017 | 436.84 Million JPY | -53.15% |
| 2016 | 932.37 Million JPY | -19.66% |
| 2015 | 1.16 Billion JPY | -64.06% |
| 2014 | 3.22 Billion JPY | 1480.73% |
| 2013 | 204.28 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -2.5 Million JPY | -2.42% |
| 2024 Q1 | -2.44 Million JPY | -2.09% |
| 2023 Q4 | -2.39 Million JPY | 31.32% |
| 2023 Q3 | -3.48 Million JPY | 14.92% |
| 2023 Q1 | -4.53 Million JPY | 14.56% |
| 2023 FY | -14.5 Million JPY | 41.08% |
| 2023 Q2 | -4.09 Million JPY | 9.72% |
| 2022 Q4 | -5.3 Million JPY | 18.12% |
| 2022 Q2 | -6.5 Million JPY | -2.94% |
| 2022 FY | -24.61 Million JPY | 81.42% |
| 2022 Q1 | -6.31 Million JPY | 74.67% |
| 2022 Q3 | -6.48 Million JPY | 0.34% |
| 2021 Q4 | -24.94 Million JPY | 25.36% |
| 2021 FY | -132.46 Million JPY | -77.92% |
| 2021 Q1 | -32.95 Million JPY | 0.0% |
| 2021 Q2 | -41.15 Million JPY | -24.89% |
| 2021 Q3 | -33.41 Million JPY | 18.8% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q4 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 FY | -74.45 Million JPY | -16756.6% |
| 2020 Q1 | - JPY | -100.0% |
| 2019 FY | 447 Thousand JPY | -39.68% |
| 2019 Q4 | 22.88 Million JPY | 768.28% |
| 2019 Q3 | -3.42 Million JPY | -101.44% |
| 2019 Q2 | 238.37 Million JPY | 25.86% |
| 2019 Q1 | 189.39 Million JPY | 9.65% |
| 2018 Q4 | 172.72 Million JPY | 12.67% |
| 2018 Q3 | 153.29 Million JPY | -40.38% |
| 2018 Q2 | 257.14 Million JPY | 62.29% |
| 2018 Q1 | 158.45 Million JPY | 32.91% |
| 2018 FY | 741 Thousand JPY | -99.83% |
| 2017 Q3 | 121.37 Million JPY | -3.72% |
| 2017 Q1 | 123.87 Million JPY | -29.03% |
| 2017 FY | 436.84 Million JPY | -53.15% |
| 2017 Q4 | 119.21 Million JPY | -1.78% |
| 2017 Q2 | 126.05 Million JPY | 1.76% |
| 2016 Q3 | 73.67 Million JPY | 25.42% |
| 2016 Q4 | 174.53 Million JPY | 136.91% |
| 2016 FY | 932.37 Million JPY | -19.66% |
| 2016 Q2 | 58.73 Million JPY | -90.61% |
| 2016 Q1 | 625.59 Million JPY | 732.35% |
| 2015 Q3 | 688.23 Million JPY | 443.82% |
| 2015 FY | 1.16 Billion JPY | -64.06% |
| 2015 Q1 | 284.69 Million JPY | 160.91% |
| 2015 Q2 | 126.55 Million JPY | -55.55% |
| 2015 Q4 | 75.16 Million JPY | -89.08% |
| 2014 FY | 3.22 Billion JPY | 1480.73% |
| 2014 Q4 | 109.11 Million JPY | 0.0% |
| 2013 FY | 204.28 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 100.771% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 118.061% |
| GNI Group Ltd. | 22.43 Billion JPY | 100.065% |
| Linical Co., Ltd. | 3.77 Billion JPY | 100.384% |
| Trans Genic Inc. | 2.24 Billion JPY | 100.645% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 114.762% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 100.584% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 101.122% |
| AnGes, Inc. | -3.06 Billion JPY | 99.527% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 91.839% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 100.15% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 102.804% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 113.072% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 101.0% |
| CanBas Co., Ltd. | -984 Million JPY | 98.526% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 103.703% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 100.876% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 103.639% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 101.395% |
| PeptiDream Inc. | 17.21 Billion JPY | 100.084% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | 147.391% |
| Ribomic Inc. | -10.5 Million JPY | -38.107% |
| Healios K.K. | 108 Million JPY | 113.43% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | -4153.372% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 75.436% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | -859.259% |
| StemRIM | -44.34 Million JPY | 67.296% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 100.455% |
| FunPep Company Limited | -680.28 Million JPY | 97.868% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 120.944% |
| Stella Pharma Corporation | 217.29 Million JPY | 106.675% |
| TMS Co., Ltd. | -6.95 Million JPY | -108.691% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 104.611% |
| Cuorips Inc. | 9.63 Million JPY | 250.597% |
| K Pharma,Inc. | 910 Million JPY | 101.594% |
| Takara Bio Inc. | 25.45 Billion JPY | 100.057% |
| ReproCELL Incorporated | 1.1 Billion JPY | 101.313% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 101.214% |
| StemCell Institute Inc. | 1.57 Billion JPY | 100.92% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 100.87% |
| CellSeed Inc. | 107.15 Million JPY | 113.536% |